Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease

Phase 2 Study of Adenovirus Hepatocyte Growth Factor for Treatment of Ischemic Heart Disease

To explore the safety and efficiency of adenovirus-hepatocyte growth factor(Ad-HGF) treatment in ischemic heart disease.

1. Ischemic heart disease refers to a group of closely related syndromes by an imbalance between the myocardial oxygen demand and the blood supply.
2. Gene therapy offers an attractive alternative to current pharmacologic therapies and may be beneficial in refractory disease. Gene therapy with hepatocyte growth factor induces angiogenesis, decreases apoptosis and leads to protection in the ischemic heart. In this study, we mainly explore the safety and effects of adenovirus hepatocyte growth factor for the treatment of ischemic heart disease.

Inclusion Criteria:

• person with ischemic heart disease;
• Male or female of 20 to 70 years old;
• No blood perfusion detected in some area of heart using Single-Photon Emission Computed Tomography(SPECT) or Magnetic Resonance Imaging(MRI)
• two or more than two coronary arteries lesions were detected using coronary artery angiography and at least one coronary artery are un-suitable for percutaneous coronary intervention (PCI) or Coronary artery bypass grafting (CABG)；Or patients refuse to perform PCI or CABG
• LVEF is ≤45%;
• Patients must sign approved informed consent.

Exclusion Criteria:

• Acute myocardial infarction occured within one week
• CABG performed within 6 months or PCI performed within 3 months
• Patients with systemic active infection
• Blood alanine aminotransferase (ALT)>135mmol/L or blood crea(Cr)>200umol/L or patients with chronic obstructive pulmonary disease (COPD)
• patients with obvious bleeding tendency and blood disease
• patients with malignant tumor or end-stage disease
• patient anticipated life expectancy is less than 12 months
• patient recently attended test drugs or other device research